• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1243689 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& R% D/ {9 ]' G
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ; j) s4 e4 }, Z% r
+ Author Affiliations7 L  k1 l6 P2 c* _$ w# g

3 r& ~1 I' p) Y5 Q4 P0 |1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 7 Y) N. X% X1 a* ]9 l8 j
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ @( M1 y/ b* x2 z* O; N1 f3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* R) h2 X9 Q- p0 G. k4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 1 @5 R* V' O1 a. m0 ?7 y) L7 y
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
- A5 y8 ~3 s  j$ F- D7 N6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 4 I! Z$ w0 f( I+ [- L3 a4 q3 a
7Kinki University School of Medicine, Osaka 589-8511, Japan
% o. t- _; ?' W9 k- D8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 b8 a7 K8 a2 s7 i1 p; h
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& J$ A) E& |0 ~, dCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
; |4 C3 X+ ?, j1 I3 v2 x# H9 rAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / `* {2 @9 K; q; ]1 H4 @/ _4 t8 x

( G7 r5 C# s+ d$ K" }) i
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 7 _! n9 M! W2 \3 M+ G$ J% s/ @

  {7 `# \. L* @/ EAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato - P) d- e0 c! H7 \1 y

9 `: n4 ?; z9 |' zAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
/ N% A# u$ {, V6 N
4 k* O7 R8 B1 K  m! CPublished online on: Thursday, December 1, 2011
5 X2 v, R" g! e0 ?$ Y
- H1 Q% f* }( M7 j0 }Doi: 10.3892/ol.2011.507 1 J$ p$ h/ j9 E; `6 b
4 O% S% i  F% d  g, l$ p: P
Pages: 405-410 : L+ A) p0 a  R* b( O9 b- t
% \9 u+ N6 ?. e% I
Abstract:
$ Q0 O3 i% S, r) M2 A+ xS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma./ a6 ~8 |) P. A) ^
8 W# ~3 m4 S& G% ~
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population6 N( ^$ [0 J5 v% L0 P
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
6 J. y' e# }3 Q; \+ [+ Author Affiliations
7 @! M: D. i2 M; t1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
) b1 F/ w- w5 @% W2Department of Thoracic Surgery, Kyoto University, Kyoto
3 H$ z, S2 J% H! a; K' l3 G& c3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan   B5 C/ F( l4 ]2 }+ }- |
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
, K! L! D  J7 |3 h" i- xReceived September 3, 2010. 7 p$ S2 X7 }) {! F/ V
Revision received November 11, 2010. 2 H# t0 Z5 H8 u  o* H, L* B
Accepted November 17, 2010.
2 H# R( A1 v5 Y% `" B+ @Abstract7 P& t/ H7 Z  ?7 G2 U2 F
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 3 e& F2 D' I- b3 y( ~) A
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 9 y! K8 P& A7 I7 b/ T  V
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
& T% o$ e4 e4 OConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
1 ?! r5 t% T/ [; p7 v8 S7 |6 x
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。+ w5 E, a8 e' c* ], [
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?4 X8 P& ~1 i+ R2 m3 F
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy8 u; S1 W" |1 r+ r3 s
http://clinicaltrials.gov/ct2/show/NCT01523587& h8 C3 p' R; M8 q! y! B

. `- z) x" m0 ?( ~* [BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC" e& `, }, y. W+ D8 v3 P( V* G& c- p5 s
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 # G- v/ i% D, g. t( P
8 C* e% h. s0 M6 @8 b0 K' w5 ]
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: A0 x& G6 O2 y/ P" W- ?  k至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 # a  v1 ^4 \/ f; G
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。6 c* V& z) W; U* \( j+ j
至今为止,未出 ...

9 E6 e. `- P7 P, |  \4 W没有副作用是第一追求,效果显著是第二追求。
. U3 A& R: {( X/ b& E0 J4 z. W- v2 E不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表